The smaller pharma companies I find it tough to evaluate, so many of them can potentially do well but I do not have the bandwidth to go molecule by molecule and evaluate those companies. But I think Sun Pharma is a decent business model, so we are just holding it for the long term.
Positive macro already priced in, market needs fresh earnings trigger: Sanjeev Prasad
Kotak Institutional Equities’ Sanjeev Prasad observes the Nifty 50 index is range bound. Valuations are expensive, but macroeconomics are decent. Earnings growth faces challenges from
June 4, 2025